The company said that its trial data also show that patients with wild-type SIGMAR1 and COL24A1 genes may experience ...

GLP-1 receptor agonist indications continue to expand beyond glycaemic and weight control, with benefits now shown in chronic ...

A key Alzheimer’s drug has finally revealed its secret. Researchers discovered that lecanemab works by activating the brain’s immune cells—but only through a specific part of the antibody called the ...

Scientists reverse Alzheimer's memory loss in mice by using NAD+ to restore brain energy, defying decades of research.

The NHS will reconsider approving two Alzheimer’s “wonder drugs” after a successful appeal. The National Institute of Health ...

Oral semaglutide (a GLP-1 pill) is not effective at slowing progression in patients with mild Alzheimer's disease, finds the ...

Scientists have long been racking their brains to crack the mechanism behind Alzheimer’s disease progression. They may have ...

Add Yahoo as a preferred source to see more of our stories on Google. THERE'S BEEN A wave of new therapies for Alzheimer’s disease released over the last few years. But nothing would be as ...

Research from UC Santa Cruz indicates that the P3 peptide—an alternative cleavage product of the amyloid precursor ...

A new drug, FLAV-27, targets epigenetic changes in Alzheimer’s. In preclinical studies, the drug reduced levels of ...

Medication-related cognitive impairment is common, mimics neurodegenerative disease, increases with polypharmacy, and may be prevented with regular cognitive assessment monitoring.